As the average price of regular-grade gas in the United States speeds past $4.30 a gallon, many patients with cancer may be wondering how they can afford to get to and from cancer treatments. Luckily, there’s assistance to make travel less expensive.
Unlike stem cell transplant, which has strict eligibility criteria, the majority of patients with blood cancer may be able to receive CAR-T cell therapy, regardless of other comorbidities, explained an expert.
Despite several FDA drug approvals over the past few years in the cholangiocarcinoma space, many patients are ineligible for these treatments as a first option, signaling a significant unmet need.
As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about improving patient-physician communication throughout myeloma care.
As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about treating myeloma as a chronic disease and how the multidisciplinary approach to care can assist in challenges, like financial toxicity.
Hear from our 2021 Metastatic Breast Cancer Heroes™ award winners as they discuss their dedication to the field and how to drive attention and awareness to metastatic disease, how patients can self-advocate and find the right support and resources and advancing diversity and inclusion in metastatic breast cancer.
As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about raising awareness for multiple myeloma, and why sharing one’s story is helpful for others.
On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about the long-term care of MPNs.
On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about MPN resources and support groups available to patients and loved ones.
On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Shireen Sirhan, from the Jewish General Hospital-McGIll University, about patients being their own best advocate in their MPN care.
On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Shireen Sirhan, from the Jewish General Hospital-McGIll University, about finding a care team that specializes in MPNs.
On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about the role of caregivers after an MPN diagnosis.
After realizing that alcohol and spicy foods were excruciating to consume after treatment, throat cancer survivor Rob Paulsen learned that smoothies were a much healthier — and more soothing — option.
Two experts explain how early-stage non-small cell lung cancer treatment has changed in recent years, particularly in the adjuvant setting, and offer future perspectives in this space.
“Coping for me has been routine-based, and that is making sure I do the things that are in my day that are really foundationally making me feel joyful,” says a survivor of an advanced-stage cancer on how to cope with “scanxiety.”
As part of its CURE Speaking Out video series, CURE spoke with Jessica Storm, a patient with metastatic triple-negative breast cancer, about learning of her diagnosis and her advice for others based on her experience.
As part of its CURE Speaking Out video series, CURE spoke with Natalia Green, senior producer and co-host of Our MBC Life, about the importance of patient-physician communication and its impact on treatment decision-making.
As part of its CURE Speaking Out video series, CURE spoke with Shirley Mertz, president of the Metastatic Breast Cancer Network, about finding support after a metastatic breast cancer diagnosis.
Dr. Jessica Donington provides an overview of key ongoing clinical trials of systemic adjuvant therapy in early non-small cell lung cancer.
An expert surgeon explains the role patients have in adjuvant therapy selection for early non-small cell lung cancer.
Dr. Martin Dietrich reviews some factors to consider when selecting an adjuvant therapy for early non-small cell lung cancer.
Jessica Donington, MD, MSCR, describes how she discusses adjuvant therapy with patients diagnosed with early non-small cell lung cancer.
An expert oncologist details the design, outcomes, and clinical implications of the IMpower010 trial.
Dr. Jessica Donington explains how the results of the ADAURA trial changed the treatment algorithm in the adjuvant setting in early non-small cell lung cancer.
Lorelei Colbert was diagnosed with triple-negative breast cancer at 28 and used her experience to launch the “Chemo to Kindness” challenge that inspired others around the world to do acts of good.
Martin Dietrich, MD, PhD, describes the toxicity profiles of chemotherapy agents used in the adjuvant setting in early non-small cell lung cancer.
Two experts detail the use of adjuvant therapy, including chemotherapy, in treating early non-small cell lung cancer.
While robotic navigational bronchoscopy is an exciting advancement in diagnosing and staging lung cancer, the procedure does come with some risks and factors to consider, explained one expert.
An infectious disease expert explains the new and upcoming treatment modalities that are improving COVID-19 outcomes for patients with cancer and other conditions that compromise the immune system.
After not knowing quite what to expect from her first chemotherapy treatment, colorectal cancer survivor Yla Flores describes the pain she felt in her heart after seeing other patients in worse conditions.
